Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Gerratana

Showing results (71-80 of 127) with videos related to

Pageof 13
Sort By:
Cancers|June 2, 2021
Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast CancerCarolina Reduzzi, Serena Di Cosimo, Lorenzo Gerratana, et al.
Breast Cancer Research and Treatment|June 2, 2021
Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancerAmi N Shah, Kristen J Carroll, Lorenzo Gerratana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2020
The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast CancerSaya Jacob, Andrew A Davis, Lorenzo Gerratana, et al.
Breast (Edinburgh, Scotland)|April 18, 2026
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert ConsensusCarmine De Angelis, Dario de Biase, Lorenzo Gerratana, et al.
International Journal of Molecular Sciences|August 27, 2021
Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC)Yulan Gong, Rajeswari Nagarathinam, Maria F Arisi, et al.
Future Oncology (London, England)|August 11, 2020
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancerSilvio Ken Garattini, Marta Bonotto, Luca Porcu, et al.
Breast (Edinburgh, Scotland)|November 13, 2016
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysisMarta Bonotto, Lorenzo Gerratana, Massimo Di Maio, et al.
Cancers|August 28, 2019
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic BiomarkerGiacomo Pelizzari, Debora Basile, Silvia Zago, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 9, 2023
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposureRossana Roncato, Elena Peruzzi, Lorenzo Gerratana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2025
Molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): using real-world data to describe this unique clinical entityAndrew A Davis, Ellen Jaeger, Ian S Hagemann, et al.
Pageof 13

Showing results (71-80 of 127) with videos related to

Sort By:
Pageof 13
Cancers|June 2, 2021
Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast CancerCarolina Reduzzi, Serena Di Cosimo, Lorenzo Gerratana, et al.
Breast Cancer Research and Treatment|June 2, 2021
Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancerAmi N Shah, Kristen J Carroll, Lorenzo Gerratana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2020
The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast CancerSaya Jacob, Andrew A Davis, Lorenzo Gerratana, et al.
Breast (Edinburgh, Scotland)|April 18, 2026
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert ConsensusCarmine De Angelis, Dario de Biase, Lorenzo Gerratana, et al.
International Journal of Molecular Sciences|August 27, 2021
Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC)Yulan Gong, Rajeswari Nagarathinam, Maria F Arisi, et al.
Future Oncology (London, England)|August 11, 2020
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancerSilvio Ken Garattini, Marta Bonotto, Luca Porcu, et al.
Breast (Edinburgh, Scotland)|November 13, 2016
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysisMarta Bonotto, Lorenzo Gerratana, Massimo Di Maio, et al.
Cancers|August 28, 2019
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic BiomarkerGiacomo Pelizzari, Debora Basile, Silvia Zago, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 9, 2023
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposureRossana Roncato, Elena Peruzzi, Lorenzo Gerratana, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2025
Molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): using real-world data to describe this unique clinical entityAndrew A Davis, Ellen Jaeger, Ian S Hagemann, et al.
Pageof 13